EMA CHMP Recommends Approval for Six Biosimilars
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recently gave the stamp of approval to six biosimilar medicines at its December meeting. One of the highlights was South Korea’s Celltrion’s Avtozma (tocilizumab), designed to treat a range of conditions including rheumatoid arthritis, systemic juvenile idiopathic arthritis, and even COVID-19 complications.
Celltrion had additional biosimilars recommended at the meeting, showcasing the company’s commitment to providing effective treatment options for various health conditions.
For further details on these biosimilars and other industry news, you can explore our full range of articles and interviews by registering for a free trial. Gain access to exclusive features and commentary from experts in the pharmaceutical and biotechnology field for a week. If you’re already a registered user, simply log in to continue reading.
Stay informed with daily news updates, analysis, and insights on key industry events by subscribing to our service. With unfettered access to the latest developments in pharma and biotech, you’ll be ahead of the curve on clinical trials, regulatory changes, mergers and acquisitions, and more. Let us help you stay in the loop with comprehensive coverage of the latest trends shaping the industry.
Join us to receive the latest updates on the biosimilars market and other significant advancements in the pharmaceutical and biotechnology sectors. Sign up today to stay informed and connected with industry leaders.
